<DOC>
	<DOCNO>NCT02361957</DOCNO>
	<brief_summary>RATIONALE : The underlie etiology inflammatory bowel disease Ulcerative Colitis yet fully understood . Studies suggest relation high intestinal permeability aberrant change epithelium . Dysbiosis intestinal microbiota might cause . Probiotics may restore balance intestinal microbiota . In theory could improve intestinal permeability therefore reduce disease activity maintain remission patient Ulcerative Colitis . OBJECTIVE : To investigate whether specifically design multispecies probiotic mixture ( ecologic 825® ) , adjuvant therapy , contribute improvement intestinal permeability , microbiota composition , disease activity inflammatory marker ulcerative colitis . STUDY DESIGN : 12-wk placebo-controlled randomize double-blind intervention 2 parallel arm . STUDY POPULATION : Adults diagnose left side Ulcerative Colitis Pancolitis remission mild stage disease . For inclusion patient Patient Simple Clinical Colitis Activity Index ( P-SCCAI ) use . INTERVENTION : Patients receive either two daily dosage 3 g Ecologic® 825 two daily dos 3 g placebo , contain carrier material ( produce Winclove Probiotics ) . MAIN STUDY PARAMETERS/ENDPOINTS : Main study parameter intestinal permeability measure several technique : lactulose/mannitol absorption test ( L/M test ) , LPS level blood serum faecal zonulin . Secondary , inflammation measure faecal calprotectin blood c-reactive protein ( CRP ) level . Furthermore sample store measure cytokine concentration serum analyse microbial composition faecal sample use HITchip . For disease relate quality life irritable bowel disease questionnaire ( IBD-Q ) SF-36 use . All parameter measure three time point ; t=0 , t=6 t=12 week .</brief_summary>
	<brief_title>The Effect Multispecies Probiotic Ecologic 825 Versus Placebo Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosed Ulcerative Colitis ( leave side UC pancolitis ) Age 1865 ( microbiota change old age ) Stable disease activity ( clinical remission CRP level &lt; 10mg/L calprotectin &lt; 100 ug/g ) measure baseline Mild disease activity ( PSCCAI &lt; 5 ) Mesalazine medication medication UC maximum intake 2.4 g/day History intestinal surgery might interfere outcome study Diabetes Mellitus ( medication dependent ) Current use antibiotic Current use corticosteroid ( 30 day prior first baseline measurement ) . Treatment medication besides mesalazine ( NSAIDs , topical systemic steroid , immunosuppressive drug aspirin ) one week prior first baseline measurement . Use pre probiotic willing stop 2 week intervention period Hypersensitivity allergy milk protein , soy protein gluten Alcohol abuse ( male 14 serving week , female 7 serving week ) Female patient : currently pregnant breastfeed intend become pregnant study Patients foreseen need GI surgery study period Patients history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>